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310Objective: Although the procedural feasibility of transcatheter aortic valve implantation has been shown by
multiple groups, longer-term data are rare. We report on 2-year follow-up clinical and echocardiographic results
after transcatheter aortic valve implantation in 227 patients.
Methods: Patients’ mean age was 81  7 years, 59% were female, mean European System for Cardiac Oper-
ative Risk Evaluation was 21%  14%, mean Society of Thoracic Surgeons score was 7%  5%, and access
routes were transfemoral (n ¼ 164), transapical (n ¼ 54), axillary (n ¼ 5), or transaortic (n ¼ 4). A CoreValve
(Medtronic Inc, Minneapolis, Minn) prosthesis was implanted in 174 patients, and a SAPIEN prosthesis (Ed-
wards Lifesciences, Irvine, Calif) was implanted in 53 patients. Clinical and echocardiographic investigations
were performed at 6 months, 1 year, and 2 years.
Results: Survival was 88.5% at 30 days, 75.9% at 6 months, 74.5% at 1 year, and 64.4% at 2 years. Patients
improved significantly in New York Heart Association class after 6 months (from 3.2  0.5 to 1.7  0.7,
P< .001) and up to 2 years (1.9  0.7). Cumulative incidences of myocardial infarction, stroke, and life-
threatening or major bleeding were 2.7%, 6.2%, and 16.2% at 2 years, respectively. The postprocedural
mean transprosthetic gradient was 12 4mmHg for all valves and did not change up to 2 years, and the effective
orifice area was 1.5  0.4 cm2 with no change over 2 years of follow-up. Moderate or severe prosthetic regur-
gitation was present in 8% of patients at 2 years. In 6% of patients, the paravalvular or valvular regurgitation
grade increased significantly over time.
Conclusions: With excellent functional recovery of the patients, good systolic valve function, and overall low
morbidity at 2 years, transcatheter aortic valve implantation may be considered the treatment of choice for aortic
valve stenosis in elderly patients with an increased risk for surgery with a heart–lung machine. (J Thorac
Cardiovasc Surg 2012;143:310-7)A growing elderly population has resulted in an increase of
the number of patients with severe aortic valve stenosis.
Surgical aortic valve replacement (SAVR) is the gold stan-
dard to treat severe aortic stenosis with proven effectiveness
and long-term results. However, a significant number of
elderly patients are not treated surgically for increased
operative risk.1 Advancements in transcatheter technology
have led to the innovation of transcatheter aortic valve
implantation (TAVI), with the first patient treated in
2002 by Cribier and colleagues.2 With its less-invasive
character by avoiding cardiopulmonary bypass and median
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The Journal of Thoracic and Cardiovascular Surgcandidates at high surgical risk and improve the usually
poor prognosis of the natural history of severe aortic
stenosis.
Data from the randomized PARTNER trial cohort A3 re-
cently demonstrated noninferiority of TAVI compared with
SAVR treatment with a 1-year follow-up. The most recent
publications of several registry studies demonstrated repro-
ducible results up to 1 year.4-6 These findings may lead to
a broader application of TAVI in elderly patients. The
next step must be to collect longer-term data to prove the
effectiveness and durability of this new treatment option.
At the German Heart Center Munich, a transcatheter
valve program was initiated in 2007. A total of 580 patients
who were considered at high operative risk by clinical judg-
ment and clinical scores (European System for Cardiac Op-
erative Risk Evaluation and Society of Thoracic Surgeons
score) have been treated with catheter-based aortic valve
implantation by transfemoral, transapical, transsubclavian,
or direct ascending aortic access since then.
A total of 227 patients have completed 2 years of follow-
up and form the study population, which is, to the best of our
knowledge, the largest series from a single center with
2 years of data. The goals of this article are therefore to as-
sess mortality, morbidity, and valve function beyond theery c February 2012
TABLE 1. Patient baseline characteristics (n ¼ 227)
Parameter Mean ± SD, or n (%)
Mean age, y 81  7
Female 134 (59%)
Logistic euroSCORE 21%  14%
STS score 7%  5%
BNP value 7100  14,000 U/L
Mean annulus diameter 23  2 mm
Mean aortic valve area 0.6  0.2 cm2
Mean aortic gradient 48  17 mm Hg
Implanted valve
CoreValve (Medtronic Inc, Minneapolis, Minn) 174 (77%)
SAPIEN (Edwards Lifesciences, Irvine, Calif) 53 (23%)
Access site
Transfemoral 164 (72%)
Transapical 54 (24%)
Subclavian artery 5 (2%)
Abbreviations and Acronyms
EOA ¼ effective orifice area
LVOT ¼ left ventricular outflow tract
NS ¼ not significant
SAVR ¼ surgical aortic valve replacement
TAVI ¼ transcatheter aortic valve implantation
VARC ¼ Valve Academic Research Consortium
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uation. To achieve comparability to other reports, the data
were prepared according to the end point definitions re-
cently published by the Valve Academic Research Consor-
tium (VARC).7Ascending aorta 4 (2%)
Coronary heart disease 118 (52%)
Peripheral vessel disease 61 (27%)
Cerebrovascular disease 41 (18%)
Previous stroke 26 (11%)
Pulmonary hypertension>60 mm Hg 53 (23%)
Previous cardiac surgery 42 (19%)
Atrioventricular valve disease 44 (19%)
Lung disease 52 (23%)
Porcelain aorta 15 (7%)
Atrial fibrillation 51 (22%)
NYHA class III or IV 218 (96%)
Ejection fraction<35% 42 (19%)
Renal insufficiency (creatinine>1.5 mg/dL) 48 (21%)
SD, Standard deviation; STS, Society of Thoracic Surgeons; BNP, brain natriuretic
peptide; euroSCORE, European System for Cardiac Operative Risk Evaluation.MATERIALS AND METHODS
Patients and Aortic Valve Implantation Technique
Between June 2007 and March 2009, 227 patients underwent TAVI for
severe aortic stenosis. Since the introduction of the TAVI program at the
German Heart Center Munich in 2007, all patients with severe aortic steno-
sis at high risk for conventional cardiac surgery with sternotomy and car-
diopulmonary bypass are referred to a TAVI multidisciplinary team
discussion by cardiac surgeons, interventional cardiologists, and cardioa-
nesthesiologists. The baseline patient characteristics of the study group
are summarized in Table 1. Choice of access site (transfemoral, subclavian,
transapical, transaortic) was based on a ‘‘transfemoral first’’ approach.8,9 If
a transfemoral access was not feasible because of diseased peripheral
vessels, a subclavian artery or transapical implantation was considered.
The transaortic approach was used as a bail-out in selected patients. In
this early-experience population, we mainly used the CoreValve prosthesis
(Medtronic Inc, Minneapolis, Minn) if a transfemoral access was eligible,
because the smaller introduction sheaths (22F) for the SAPIEN (Edwards
Lifesciences, Irvine, Calif) prosthesis were not yet available. The logistic
European System for Cardiac Operative Risk Evaluation and Society of
Thoracic Surgeons score were not different among patients treated with
a CoreValve or a SAPIEN prosthesis. Decisions were based on preproce-
dural imaging diagnostics (computed tomography scan, angiography, and
transesophageal and transthoracic echocardiography) performed in all
patients.
All implantations were performed in a hybrid theater. Patients were
treated under general anesthesia in the study population. Transfemoral
TAVI was carried out with the use of percutaneous closure devices or after
surgical cut-down of the femoral artery in case of vessel calcifications or
severe obesity. The subclavian artery was dissected free for access
through a 4- to 5-cm left or right infraclavicular incision. Transapical
valve implantation was performed via a left anterolateral minithoracot-
omy. For transaortic access, an upper median ministernotomy was
performed. After balloon valvuloplasty during rapid ventricular pacing,
valve deployment was performed under fluoroscopy on the beating heart
in case of the self-expanding CoreValve implantation and during an epi-
sode of rapid ventricular pacing in case of the balloon-expanding SAPIEN
implantation.
After TAVI, all patients were referred to an intensive care unit and mon-
itored for at least 1 day. Heart rate monitoring was continued until dis-
charge. Platelet inhibition was performed by the application of aspirin
100mg per day lifelong in all patients. After retrograde TAVI, an additional
dose of 75mg clopidogrel was administered for 6 months postprocedurally.
Patients with an indication for warfarin therapy received aspirin and
warfarin without clopidogrel.The Journal of Thoracic and CaFollow-up
Clinical and echocardiographic follow-up data were collected at dis-
charge, 6 months, 1 year, and 2 years after the procedure.
Echocardiographic investigations were performed by an experienced
echocardiographer with an HP Sonos 5500 and HP Sonos 7500 (Hewlett
Packard, Palo Alto, Calif). Peak and mean systolic pressure gradients in
the left ventricular outflow tract (LVOT) 1 cm below the valve and across
the valve were measured in an apical 3- or 5-chamber view using pulsed-
wave Doppler for the LVOT measurements and continuous-wave Doppler
for the valve measurements, respectively. The LVOT diameter was
measured 1 cm below hinge points of the visible prosthetic leaflets from
the inner edges of the stent in a parasternal long-axis zoom view. In patients
with sinus rhythm, 3 of the best available signals were averaged. If atrial
fibrillation was present, a minimum of 5 measurements was averaged. Ef-
fective orifice area (EOA) was obtained by using the continuity equation.10
Prosthetic regurgitation was assessed by a semiquantitative approach using
the extent of the regurgitant jet length (color Doppler), pressure half-time
measurement (continuous-wave Doppler), in case of transvalvular regurgi-
tation vena contracta measurement, and in case of paravalvular leakage
estimation of percentage of circumference. The severity of regurgitation
was graded as none, mild, mild–moderate, moderate, moderate–severe,
and severe.
Echocardiographic data were available in 203 of 203 living patients
(100%) at discharge, 132 of 159 living patients (83%) at 6 months, 119
of 157 living patients (76%) at 1 year, and 90 of 140 living patients
(64%) at 2 years.rdiovascular Surgery c Volume 143, Number 2 311
FIGURE1. Two-yearKaplan–Meier survival curve of the studypopulation
(227 patients). On the x-axis, the time after TAVI is shown in days. Survivals
at 30 days, 6 months, 1 year, and 2 years were 88.5%, 75.9%, 74.5%, and
64.4%, respectively. TAVI, Transcatheter aortic valve implantation.
TABLE 2. Periprocedural and two-year morbidity
Event
Periprocedural
(72 h) N (%)
Cumulative at
2 y N (%)
Myocardial infarction 4 (1.8%) 6 (2.7%)
Stroke
Stroke 6 (2.6%) 15 (6.6%)*
TIA 1 (0.4%) 2 (0.9%)
Bleeding
Life-threatening/disabling 11 (4.8%) 26 (11.4%)
Major 1 (0.4%) 11 (4.8%)
Minor 1 (0.4%) 12 (5.3%)
Acute kidney injuryy
Stage 2 23 (10.1%) –
Stage 3 18 (7.9%)
Vascular complications –
Major 18 (7.9%)
Minor 34 (15.0%)
TIA, Transient ischemic attack. *Stroke rate was 1 of 54 (2%) in transapically treated
patients versus 14 of 173 (8%) in retrogradely treated patients, NS. yStage 1 was not
assessed.
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in our outpatient clinic, from telephone calls, and from medical reports.
End Point Definitions
Primary end point was all-cause mortality. Causes of death were re-
ported according to the VARC definitions7 and the guidelines to report mor-
bidity and mortality after valve procedures.11 Myocardial infarction,
stroke, bleeding, acute kidney injury, vascular complications, and the com-
bined efficacy end point at 2 years were reported according to the VARC
definitions.7
Statistics
Continuous variables are presented as means  standard deviation.
Categoric variables are presented as simple percentages. Kaplan–Meier
estimator curves are used to display survival, freedom from stroke, and
freedom from bleeding events within 2 years after TAVI. A paired t test
was performed to evaluate changes in NYHA classification, self-assessed
health state, valve areas, and gradients.
All data were analyzed with SPSS software (v. 17 for Windows; SPSS
Inc, Chicago, Ill).RESULTS
Two-Year Survival
Survivals at 30 days, 6 months, 1 year, and 2 years were
88.5%, 75.9%, 74.5%, and 64.4%, respectively. The
course of the Kaplan–Meier survival curve (Figure 1) dem-
onstrates that the majority of deaths occurred within 6
months. Beyond that, the curve shows a slow decline. There
was no difference in survival between patients treated by
antegrade or retrograde implantation route (P ¼ .254, log-
rank test) or between patients receiving a CoreValve or312 The Journal of Thoracic and Cardiovascular SurgSAPIEN prosthesis (P ¼ .169, log-rank test). By using
the definitions by Akins and colleagues,11 causes of 87
deaths within 2 years were valve-related in 30% of patients,
cardiac in 14% of patients, and noncardiac in 44% of pa-
tients, whereas 12% of data were missing. By using the
new VARC end point definitions for TAVI trials,7 causes
of death were cardiovascular in 65 patients (75%) and
noncardiovascular in 22 patients (25%).Two-Year Morbidity and Clinical State
Periprocedural and 2-year morbidity are reported accord-
ing to the VARC criteria and summarized in Table 2.
Kaplan–Meier estimated freedoms from stroke were
94.9%, 94.3%, 94.3%, and 92.5% at 30 days, 6 months,
1 year, and 2 years, respectively. Kaplan–Meier estimated
freedom from any bleeding event (minor, major, and life-
threatening/disabling) was 90.1%, 83.7%, 80.7%, and
74.1% at 30 days, 6 months, 1 year, and 2 years, respectively.
General health state on a scale of 0% to 100%
(100% ¼ best general health state) was 52%  17% pre-
operatively and improved to 63%  21% at 6 months
(P< .001). This value stayed unchanged up to 2 years
(63%  17% at 1 year, 63%  19% at 2 years, not signif-
icant [NS], paired t test (Figure 2, A).
Mean NYHA classification was 3.2  0.5 preprocedur-
ally, improved to 1.7  0.7 (P<.001) at 6 months, stayed
unchanged between 6 months and 1 year (1.8  0.6,
P ¼ .061), and declined between 1 and 2 years to 1.9 
0.7 (P¼ .003, paired t test). The distribution of NYHA clas-
ses at different time points is shown in Figure 2, B.Valve Performance
The EOA, as measured by echocardiography, improved
significantly from 0.6  0.2 cm2 to 1.5  0.4 cm2 atery c February 2012
FIGURE 2. Clinical state after TAVI. A, Self-assessed general health state in% (100% is the best health state) at different time points. B, Distribution of
NYHA classes at different time points. CI, Confidence interval; NYHA, New York Heart Association.
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0.3 cm2), 1 year (1.5  0.3 cm2), and 2 years (1.5  0.3
cm2, NS, paired t test). Mean aortic gradients decreased sig-
nificantly from 48 17 mmHg to 12 4 mmHg (P<.001)
at discharge. No further changes were detected at 6 months
(12 5 mmHg), 1 year (13 4 mmHg), or 2 years (11 4
mm Hg, NS, paired t test). The systolic valve function data
are shown in Figure 3, A and B. Mean gradients of greaterFIGURE 3. Prosthetic valve function up to 2 years. A, EOA as measured by ech
measured by echocardiography at different time points. C, Distribution and sev
echocardiography. D, Evolution of paravalvular regurgitation. On the x-axis, t
regurgitation grade at 2 years. CI, Confidence interval; EOA, effective orifice a
The Journal of Thoracic and Cathan 20 mm Hg (defined as prosthetic heart valve dysfunc-
tion by the VARC4) occurred in 1 of 188 patients (0.5%) at
discharge and in 3 of 120 patients (2.5%), 5 of 100 patients
(5%), and 1 of 71 patients (1.4%) at 6 months, 1 year, and
2 years, respectively. EOAs of less than 1.2 cm2 (defined as
prosthetic heart valve dysfunction by the VARC7) occurred
in 29 of 175 patients (16.6%), 18 of 108 patients (16.7%),
15 of 90 patients (16.7%), and 9 of 62 patients (14.5%) atocardiography at different time points. B, Mean transprosthetic gradient as
erity of any prosthetic regurgitation at different time points as assessed by
he severity of paravalvular regurgitation at discharge is shown versus the
rea.
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finding was equally distributed among the different valve
types and sizes.
The distribution and severity of prosthetic regurgitation
are shown in Figure 3,C. A regurgitation moderate or higher
(defined as prosthetic heart valve dysfunction by theVARC7)
occurred in 22 of 203 patients (11%), 8 of 130 patients (6%),
9 of 116 patients (8%), and 7 of 89 patients (8%) at
discharge, 6 months, 1 year, and 2 years, respectively.
In regard to the evolution of paravalvular prosthetic regur-
gitation from discharge to 2 years, therewas an increase of at
least 2 of 5 regurgitation grades in less than 5% of the pa-
tients, whereas in the majority of the patients the severity
of paravalvular regurgitation improved or did not change
significantly (Figure 3, D). The incidence of higher grade
paravalvular leakages (moderate or higher) was statistically
not different between the CoreValve and the SAPIEN pros-
thesis. A clinically significant central valvular regurgitation
occurred in 3 patients (all with a SAPIEN implantation) with
a change from none at discharge to moderate (n ¼ 1), mod-
erate–severe (n ¼ 1), and severe (n ¼ 1) at 2 years.
Combined Efficacy End Point
Combined efficacy at 2 years was 52% (104/202 patients
who survived 30 days) according to the VARC criteria7 with
absence of all-cause death after 30 days, hospitalization for
symptoms of valve-related or cardiac decompensation, or
prosthetic valve dysfunction (aortic valve area< 1.2 cm2
and mean aortic valve gradient  20 mm Hg or peak veloc-
ity  3 m/s, or moderate or severe prosthetic valve aortic
regurgitation).
DISCUSSION
The new catheter-based valve treatment options will
change cardiovascular medicine toward less-invasive treat-
ment with avoidance of cardiopulmonary bypass and ster-
notomy. With the evidence of noninferiority compared
with SAVR in cohort A of the randomized PARTNER trial,3
indications and guidelines will be adopted. However, only
periprocedural noninferiority is not sufficient, and longer-
term data will be needed. Our data may add important
information of the longer-term impact of TAVI therapy.
The findings of our study with a 2 year follow-up of 227
patients after TAVI demonstrate 1) a considerable peripro-
cedural mortality, as was reported by other groups in
the early days of TAVI, and low mortality after 6 months;
2) efficacy of the treatment with persistent symptom relief;
3) a lowmorbidity rate at 2 years except for bleeding events;
and 4) a good systolic valve function, whereas prosthetic
regurgitation might need further attention.
Survival
The early mortality reported in this early-experience co-
hort is considerable with 11.5% at 30 days, which compares314 The Journal of Thoracic and Cardiovascular Surgwell with reports from other groups in 2007 and 2009 with
30-day mortality rates of 12% to 23%.12-16 More recent
studies demonstrate lower 30-day mortality rates of less
than 10%, assuming that there was a ‘‘worldwide learning
curve’’ leading to improved results in centers that started
later with more experienced proctors and improved devices.
Among our most recent 200 TAVI cases (from April 2010)
we observed a Kaplan–Meier 30-day survival of 96.6%
(Lange et al, unpublished data from theMunichHeart Center
database, 2011). The majority of deaths in the study popula-
tion occurred within 6 months. Beyond 6 months and up to 2
years, only 7.5% (17/227) of the reported patients died. Be-
cause the longer-term data are the focus of the present study,
we assume a lowmortality beyond the short-term and a dura-
ble result after TAVI. We might anticipate future 2-year sur-
vival of 85% to 90% after TAVI. This may lead to widening
the indications for TAVI for younger high-risk patients. In
contrast with data from the European PARTNER trial,3
we did not observe differences in 30-day or longer-term sur-
vival between antegrade or retrograde implantation routes.
Causes of death were cardiovascular in the majority of
the cases when reported according to the VARC definitions,
which also include unknown causes of death.7 By using the
surgical guidelines to report mortality,11 approximately half
of the deaths were noncardiac and therefore related to the
comorbidities of the patients. However, to achieve compa-
rability to future TAVI studies, it is reasonable to refer to
the VARC consensus report.
Clinical State
The short-term improvement in NYHA classification
has been reported after treatment of aortic stenosis by
TAVI.8,17,18 Our data demonstrate stable conditions at
1 year and a slight decline after 2 years with less patients
being in NYHA class I. Still, more than 80% of the patients
are in NYHA class I or II at 2 years, demonstrating the
durable effectiveness of the treatment. Self-assessed general
health state remains stable up to 2 years and is significantly
improved compared with preprocedural assessment. These
data demonstrate a durable symptom relief and thus the
longer-term effectiveness of TAVI treatment. The findings
justify also offering TAVI treatment to lower-risk octogenar-
ian patients.
Morbidity
Periprocedural incidences of myocardial infarction and
stroke rates were low and comparable to other reports,4
and only few events occurred within 2 years. Of note, in
our cohort, major stroke rate was considerably lower in
transapically treated patients (1/54 [2%] vs 14/173 [8%],
NS). The hypothesis that the risk of calcium embolization
might decrease with less manipulation in the aortic arch
via an antegrade route has been proposed19 but was not
proven by all reports.5,20 Our observation has encouragedery c February 2012
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patients with a history of cerebral infarction. Myocardial
infarction is an infrequent complication at long-term and
is usually associated with preexisting coronary heart
disease. A rare TAVI-specific procedural complication is
coronary obstruction with native calcium21,22 that may be
foreseen in patients with a narrow aortic root. In these
patients, implantation of the self-expanding CoreValve
might be beneficial. Acute kidney injury with the need for
dialysis, which occurred in 8% in the current study, is a fre-
quent problem after TAVI in an elderly cohort with a rela-
tively high incidence of preprocedural renal insufficiency.
Reports from other groups indicate 2.5% to 9% new dialy-
sis after TAVI.20,23,24 Another study from our group showed
that there was an increased in-hospital mortality in patients
with acute kidney injury and that preoperative creatinine
level is a predictor of acute kidney injury.25 Thus, in patients
with elevated creatinine levels, special attention should be
paid to fluid and electrolyte management.
Vascular complications may occur in 9% to 30% of
transfemoral TAVI cases and have been reported to have
an impact on outcomes after TAVI.26-28 Previous data
from our group29 demonstrate that there is a certain learning
curve with large sheaths and vessel closure devices that
were not constructed for these large diameters. Future tech-
niques (smaller sheaths, more optimal closure devices)
might further reduce these complications. In patients with
heavily calcified vessels, we rather opt for a surgical
cut-down.
There are few reports on bleeding events beyond proce-
dural data, the incidences ranging from 3% to 30% at
1 year.5,6 Bleeding events were frequent in the study
population with a Kaplan–Meier estimated freedom from
life-threatening or major bleeding of 80% at 2 years. Free-
dom from any bleeding event was 74% at 2 years. Some
78% (49/63) of all bleeding events occurred beyond the
periprocedural 72 hours, assuming that bleeding might be
a persistent problem after TAVI. After SAVR with biopros-
theses, freedom from bleeding is reported to be as high as
95% at 18 years30 in the typical surgical patient population
without anticoagulation, but there is evidence that hemor-
rhagic complications after SAVR increase with patient
age.31 The typical TAVI population consists of elderly pa-
tients with multiple comorbidities, and thus, dual platelet
inhibition, which is empirically administered analogous to
percutaneous coronary interventions, might significantly
increase the bleeding risk. A larger randomized study is
needed to clarify whether these elderly patients could un-
dergo TAVI without dual antiplatelet aggregation therapy.
Valve Performance
As expected for biological valves, there were stable gra-
dients and EOAs at 2 years. Criteria of valve dysfunction
were proposed by the VARC. Accordingly, few patientsThe Journal of Thoracic and Cahave an increased gradient of more than 20 mm Hg at 2
years, whereas a reduced valve orifice area of less than
1.2 cm2 was found in 14.5% of the patients. In association
with the low gradients, this finding is clinically insignifi-
cant. In addition, for EOA calculation, the LVOT measure-
ment is the most sensitive parameter. In the present study,
the LVOT diameter was measured 1cm below the hinge
points of the visible prosthetic leaflets from inner edges of
the stent in a parasternal long-axis zoom view. Other
authors measured the LVOT ‘‘just underneath the prosthe-
sis’’32 or ‘‘just below hinge points of the visible prosthetic
leaflets from inner edges of the stent.’’33 Thus, because
exact definitions for LVOT measurements with the new
catheter valves are missing, comparison of EOA data
from different groups is limited. Nonetheless, the favorable
systolic function of the catheter valves might lead to antic-
ipation of a low degeneration rate and long-term durability.
Another concern after TAVI is moderate or severe prosthetic
regurgitation, which occurred in 8% of patients at 2 years.
There is evidence of impaired in-hospital34 or 1-year6 sur-
vival with clinically relevant prosthesis regurgitation. Our
data demonstrate that paravalvular regurgitation does not
decrease in all patients after TAVI (Figure 3, D). Therefore,
new technologies addressing this problem are needed. We
also identified 3 patients after SAPIEN valve implantation
with increasing central leakage at 2 years. This finding
might be a sequel of balloon expansion of the valve or
a degenerative process.Combined Efficacy End Point
This is the first study to present the combined efficacy
end point according to the VARC criteria at 2 years. The
combined efficacy in 227 patients after TAVI at 2 years
was 52% in the current study and will have to be compared
with results from other reports.CONCLUSIONS
With excellent functional recovery of patients, good sys-
tolic valve function, and overall low morbidity at 2 years,
TAVI can be considered the treatment of choice for aortic
valve stenosis in elderly patients with increased risk for sur-
gery with a heart–lung machine. Because outcomes were
not compared with a control group, future studies are
needed to prove an advantage over conventional SAVR.
Prosthetic regurgitation and bleeding events should be
addressed in future studies for evaluation of the impact on
long-term outcomes. The combined efficacy at 2 years
was 52% in the current study and will have to be compared
with the results from other reports.References
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Dr Gregory Fontana (Los Angeles, Calif). Dr Bleiziffer, your
program in Munich is unique in that this is one of the largest TAVI
experiences in the world but includes both the balloon-expandable
and self-expanding devices, and, arguably, the most surgeon-
driven program that I am aware of. Drs. Bleiziffer and Lange
work as surgeons with all access approaches along with their car-
diologists as primary operators and should serve as a model for
other surgical programs.
We have limited data available on 2-year clinical and echocar-
diography follow-up. The data are critical to our development of
guidelines for TAVI indications. These are truly excellent results,
especially considering the series represent the initial experience
with first-generation devices and represent multiple access tech-
niques. I have 2 questions for you.
The first one is about durability. Ten of the patients had mean
gradients greater than 20 mm Hg in follow-up, and many more
had an aortic valve area less than 1.2 cm2. Were you able to iden-
tify any leaflet pathology by echocardiography or evidence of
early degeneration, and if so, did the porcine or bovine tissue per-
form differently?
Dr Bleiziffer.What I have in mind is that these small valve or-
ifice areas are somehow difficult to interpret, we think, becauseery c February 2012
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Dthere are no real echocardiography guidelines on how to measure
a transcatheter bioprosthesis. The most sensitive parameter for
EOA calculation in echocardiography is the LVOT diameter, and
it is unclear where should this be measured, below the stent, or
within the stent. There are no guidelines. What we do is we mea-
sure within the stent, and that might contribute as to why we have
slightly smaller EOAs than may be reported from other groups.We
think this is not clinically significant in terms of the very low gra-
dients we receive with catheter valves. So maybe these end point
definitions proposed by the VARC could also undergo some revi-
sion in the future.
Dr Fontana. So none of the valves that you looked at that
had these gradients (eg,>20 mm) had anything looking mor-
phologically abnormal? It was just a gradient, a physiologic
measurement?
Dr Bleiziffer. No, they did not look abnormal.
Dr Fontana. Second question. Despite your transfemoral-first
approach, your transapical and transfemoral survivals are similar,
when typically transapical carries a greater risk because of the ath-
erosclerotic burden, at least in the 30-day mortality rates in many
series. In addition, there were fewer strokes in the transapical
group, only 1, versus 14 in the transfemoral group. Have the results
of the first 227 patients influenced your algorithm for valve choice
or access strategy?
Dr Bleiziffer. Yes, it has. When patients have stroke in their
history, we would rather go for a transapical approach.
Dr Fontana. Thank you.
Dr Eric Manasse (Milano, Italy). Was the rate of readmission
during the first year of follow-up different between the cohort
of patients who had more than 1þ paravalvular regurgitation or
intra-aortic and those without regurgitation? Did you perform
autopsies in the patients who died in your area?
Dr Bleiziffer. To the first question, we did a subanalysis and
saw an increased mortality in patients who left the hospital with
a moderate or a higher grade of paravalvular regurgitation, but
these were only initial analyses, so we will have a closer look atThe Journal of Thoracic and Cathat in the future. And, no, I am not aware of autopsies that have
been performed.
Dr Manasse. Did you observe an ongoing event of strokes in
the late follow-up?
Dr Bleiziffer. Yes, but the stroke rate was low. It was 0.9% of
the patients after the postprocedural period, very low.
Dr Tufan Paker (Istanbul, Turkey). I would like to learn about
your preferred technique if the patient receiving TAVI has con-
comitant coronary artery disease. Do you deal with it at the
same time or is a second procedure done?
Dr Bleiziffer.We do it as a staged procedure. If there is any cor-
onary that needs intervention, we do it before the TAVI procedure,
becausewe think the rapid pacing that has to be done, at least for bal-
loonvalvuloplasty,would be a riskwith significant coronary stenosis.
Dr Paker. How do you explain cardiac reason for death dealing
with myocardial infarction? I mean, if you do the coronary pathol-
ogy at the same time, do you change the postoperative results?
Dr Bleiziffer. I don’t understand your question.
Dr Paker. When you look at your postoperative results, myo-
cardial infarction is one of the reasons for a cardiac nature death.
Dr Bleiziffer. Yes, but that was rare. There were some single
patients who had coronary occlusion during the procedure and
died of myocardial infarction, for example.
Dr Paker. Thank you.
Dr Leonard Girardi (New York, NY). I have 1 question for you.
On the curves that you presented out to 2 years, there were an ever-
increasing number of patients whowere no longer in NYHA class I
and an ever-increasing number of patients in II and III and even III
and IV. Have you taken a look at those patients and what are you
ascribing that change to, because you have so many patients in
III and IV to start, a very good outcome in the first 6 months, and
then it seems to be declining. Is there any reason for that?
Dr Bleiziffer. Of course, I don’t have any detailed data on that
with me, but those are elderly patients and they also have comor-
bidities, and, of course, their clinical state gets worse and within
years.rdiovascular Surgery c Volume 143, Number 2 317
